Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, has entered into an exclusive license agreement with Celera Corporation, California, USA, providing Bayer Schering Pharma with access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. These therapeutic targets were identified by Celera's proteomics discovery platform.
Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities
- Details
- Category: Novo Nordisk
Novo Nordisk has reached a settlement with the Danish Public Prosecutor for Serious Economic Crime regarding the company's sales to Iraq during 2000 to 2003 under the United Nations Oil-for-Food programme.
Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia
- Details
- Category: Lundbeck
H. Lundbeck A/S (LUN.CO; LUN DC) has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for Serdolect® (sertindole) for the treatment of schizophrenia.
Sutent Significantly Improved Progression-Free Survival
- Details
- Category: Pfizer
Pfizer has announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of cancer than the more common pancreatic adenocarcinoma. Study findings demonstrated that median progression-free survival (PFS) was 11.1 months in patients treated with Sutent compared to 5.5 months in patients treated with placebo.
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited announced a collaboration to develop macrophage-targeted compounds using Chroma's proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process.
New biological therapy Ilaris® approved in US
- Details
- Category: Novartis
The US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare but life-long auto-inflammatory disorders with debilitating symptoms and limited treatment options[1],[2],[3],[4].
Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission
- Details
- Category: Nycomed
Nycomed received marketing authorisation from the European Commission for five applications: PANTOZOL Control®, PANTOLOC Control®, PANTECTA Control®, SOMAC Control® and CONTROLOC Control®. This new OTC medication is intended for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults as a medicinal product not subject to medical prescription.
More Pharma News ...
- GSK announces a strategic alliance with Dr. Reddy's Laboratories Ltd
- Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
- Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration
- Eli Lilly and Company Announces New Drug Discovery Initiative
- Novartis demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine
- Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
- Abbott Announces Launch of Next-Generation Embolic Protection System